Anti-PCSK9 Monotherapy for Hypercholesterolemia
Top Cited Papers
- 1 June 2014
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 63 (23), 2531-2540
- https://doi.org/10.1016/j.jacc.2014.03.018
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- Eli Lilly and Company
This publication has 10 references indexed in Scilit:
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With HypercholesterolemiaCirculation, 2014
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJournal of the American College of Cardiology, 2012
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) TrialCirculation, 2010
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseNew England Journal of Medicine, 2009
- Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trialsJournal of Internal Medicine, 2009
- Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin TherapyJournal of the American College of Cardiology, 2006
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002